CD30 Ligand/TNFSF8 Antibody (116632) [DyLight 350]
Novus Biologicals, part of Bio-Techne | Catalog # FAB7741D
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunohistochemistry
Label
DyLight 350 (Excitation = 353 nm, Emission = 432 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG2A Clone # 116632
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived human CD30 Ligand/TNFSF8.
Gln63-Asp234
Accession # P32971
Gln63-Asp234
Accession # P32971
Specificity
Detects human CD30 LIgand/TNFSF8 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for CD30 Ligand/TNFSF8 Antibody (116632) [DyLight 350]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD30 Ligand/TNFSF8
Alternate Names
CD153, CD30L, TNFSF8
Additional CD30 Ligand/TNFSF8 Products
Product Documents for CD30 Ligand/TNFSF8 Antibody (116632) [DyLight 350]
Product Specific Notices for CD30 Ligand/TNFSF8 Antibody (116632) [DyLight 350]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...